Scivision Biotech (TPE:1786) Cyclically Adjusted Revenue per Share: NT$8.63 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1786 Scivision Biotech Inc TPE:1786
76 GF Score
Price NT$49.95
GF Value NT$116.00
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Scivision Biotech Cyclically Adjusted Revenue per Share?

Scivision Biotech TPE:1786 -0.89% 76 Cyclically Adjusted Revenue per Share is NT$8.63 as of Dec. 2025. GuruFocus rates TPE:1786 with a GF Score™ of 76/100 and a GF Value™ of NT$116.00 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Scivision Biotech's adjusted revenue per share for the three months ended in Dec. 2025 was NT$2.758. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$8.63 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Scivision Biotech's average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Scivision Biotech was 12.50% per year. The lowest was 11.80% per year. And the median was 11.90% per year.

As of today (2026-07-26), Scivision Biotech's current stock price is NT$49.95. Scivision Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$8.63. Scivision Biotech's Cyclically Adjusted PS Ratio of today is 5.79.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Scivision Biotech was 18.63. The lowest was 5.79. And the median was 10.89.


Scivision Biotech  (TPE:1786) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Scivision Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=49.95/8.63
=5.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Scivision Biotech was 18.63. The lowest was 5.79. And the median was 10.89.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Scivision Biotech Cyclically Adjusted Revenue per Share Related Terms


Scivision Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Scivision Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scivision Biotech Cyclically Adjusted Revenue per Share Chart

Scivision Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.52 6.16 6.83 7.87 8.63

Scivision Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.87 8.12 8.34 8.52 8.63

TPE:1786 vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Scivision Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scivision Biotech Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Scivision Biotech's Cyclically Adjusted PS Ratio falls into.


TPE:1786
76GF Score
Scivision Biotech Inc TPE:1786
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scivision Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Scivision Biotech's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=2.758/324.0540*324.0540
=2.758

Current CPI (Dec. 2025) = 324.0540.

Scivision Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.765 238.132 1.041
201606 0.639 241.018 0.859
201609 1.022 241.428 1.372
201612 1.201 241.432 1.612
201703 0.816 243.801 1.085
201706 1.299 244.955 1.718
201709 1.169 246.819 1.535
201712 1.439 246.524 1.892
201803 1.769 249.554 2.297
201806 0.858 251.989 1.103
201809 1.233 252.439 1.583
201812 1.676 251.233 2.162
201903 1.516 254.202 1.933
201906 1.499 256.143 1.896
201909 1.549 256.759 1.955
201912 1.839 256.974 2.319
202003 1.557 258.115 1.955
202006 1.587 257.797 1.995
202009 1.639 260.280 2.041
202012 2.502 260.474 3.113
202103 1.579 264.877 1.932
202106 1.884 271.696 2.247
202109 1.901 274.310 2.246
202112 1.972 278.802 2.292
202203 1.516 287.504 1.709
202206 2.000 296.311 2.187
202209 2.498 296.808 2.727
202212 1.606 296.797 1.753
202303 1.633 301.836 1.753
202306 2.542 305.109 2.700
202309 2.869 307.789 3.021
202312 2.472 306.746 2.611
202403 2.632 312.332 2.731
202406 2.888 314.175 2.979
202409 3.109 315.301 3.195
202412 3.256 315.605 3.343
202503 2.737 319.799 2.773
202506 2.875 322.561 2.888
202509 2.999 324.800 2.992
202512 2.758 324.054 2.758

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$8.63 mean?
Scivision Biotech (TPE:1786) has a Cyclically Adjusted Revenue per Share of NT$8.63 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scivision Biotech and its competitors.
Is Scivision Biotech's Cyclically Adjusted Revenue per Share too high?
Scivision Biotech's current Cyclically Adjusted Revenue per Share is NT$8.63. Overall, Scivision Biotech has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Scivision Biotech's Cyclically Adjusted Revenue per Share of NT$8.63 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scivision Biotech and its competitors. Scivision Biotech's current Cyclically Adjusted Revenue per Share is NT$8.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$116.00, compared to a current price of NT$49.95 — trading 56.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$8.63. Scivision Biotech's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current Cyclically Adjusted Revenue per Share is NT$8.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scivision Biotech (TPE:1786) Overvalued in 2026?

Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued. The current stock price of NT$49.95 is trading 56.9% below its estimated GF Value™ of NT$116.00. GuruFocus considers Scivision Biotech to be Possible Value Trap.

Key valuation signals for TPE:1786:

  • Cyclically Adjusted Revenue per Share: NT$8.63
  • GF Value™: NT$116.00 vs. price of NT$49.95 (56.9% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scivision Biotech Business Description

Address No. 1, South 1st Road, Qianzhen District, Kaohsiung, TWN, 806
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
76GF Score

Get the complete analysis for TPE:1786

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.95
Price
NT$116.00
GF Value